Self-assembled thioether-bridged paclitaxel-dihydroartemisinin prodrug for amplified antitumor efficacy-based cancer ferroptotic-chemotherapy-Reference-Cited by-同舟云学术

Self-assembled thioether-bridged paclitaxel-dihydroartemisinin prodrug for amplified antitumor efficacy-based cancer ferroptotic-chemotherapy

Published:2023 Issue:9 Volume:11 Page:3321-3334
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Zheng Yifei¹,Qin Chao¹,Li Fei¹,Qi Jingxin¹,Chu Xinyu¹,Li Hao¹,Shi Ting¹,Yan Zhen¹,Yang Lei¹^ORCID,Xin Xiaofei¹,Liu Lisha¹^ORCID,Han Xiaopeng¹^ORCID,Yin Lifang¹²³

Affiliation:

1. Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China

2. NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, China Pharmaceutical University, Nanjing 210009, China

3. Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, China; State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing 210009, China

Abstract

In this study, ROS-sensitive prodrug nanoassemblies composed of a single thioether bond bridged dihydroartemisinin-paclitaxel prodrug was constructed. The nanoassemblies with enhanced ferroptotic-chemotherapy promoted tumor cell death.

Funder

China pharmaceutical university

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2023/BM/D2BM02032G

Reference51 articles.

1. Ferroptosis-driven nanotherapeutics for cancer treatment

2. Emerging Strategies of Cancer Therapy Based on Ferroptosis